Multicenter comparison of the nifedipine gastrointestinal therapeutic system and long-acting propranolol in patients with mild to moderate systemic hypertension receiving diuretics

Frishman, William H.; Garofalo, James L.; Rothschild, Armand; Rothschild, Marylee; Greenberg, Steven M.; Soberman, Judith E.

doi:10.1016/0002-9343(87)90631-0

Cited by 17 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nifedipine is a dihydropyridine calcium channel blocker, the short acting formulation of which has been associated with refl ex sympathetic nervous system (SNS) activation leading to fl ushing, tachycardia, worsening myocardial ischemia, and cerebrovascular ischemia; therefore only longer acting formulations should be used (Gibbons et al 2003). Numerous extended-release formulations are available worldwide and have been shown to be equally effi cacious as compared to other antihypertensives such as ARBs, β-blockers, and diuretics in the management of hypertension (Frishman et al 1987;Weir et al 1996;Brown et al 2000). This review focuses on the extended-release formulations of nifedipine and their role in the treatment of patients with hypertension.…”

Section: Introductionmentioning

confidence: 99%

Long-acting nifedipine in the management of the hypertensive patient

Snider¹,

Nuzum²,

Veverka³

2008

VHRM

View full text Add to dashboard Cite

Hypertension is a global condition affecting billions worldwide. It is a signifi cant contributor to cardiovascular events, cardiac death and kidney disease. A number of medication classes exist to aid healthcare providers and their patients in controlling hypertension. Nifedipine, a dihydropyridine calcium channel blocker, was once one of the most widely used medications for hypertension, but safety and tolerability concerns along with the introduction of new classes of antihypertensive medications and an increasing pool of data showing mortality benefi t of other classes caused nifedipine to fall out of favor. More recently, long-acting formulations were developed and made available to clinicians. These newer formulations were designed to address many of the concerns raised by earlier formulations of nifedipine. Numerous clinical trials have been conducted comparing long-acting nifedipine to many of the more commonly prescribed antihypertensive medications. This review will address the pharmacology, pharmacokinetics and the available clinical trial data on long-acting nifedipine and summarize its role in the management of hypertension.

show abstract

Section: Introductionmentioning

confidence: 99%

Long-acting nifedipine in the management of the hypertensive patient

Snider¹,

Nuzum²,

Veverka³

2008

VHRM

View full text Add to dashboard Cite

show abstract

“…1,2 As the adverse effects profile of the available agents has improved, the influence on QOL has become more subtle and thus has led to substantial interest and investigation into the assessment of QOL in therapeutic trials. [2][3][4][5] Health-related QOL refers to an individual's ability to perform a range of roles in society and to reach an acceptable level of satisfaction from functioning in those roles. 6,7 There is general agreement that a comprehensive and universal QOL assessment is unlikely to ever be achieved, probably because the precise elements contributing to QOL can vary substantially in different individuals.…”

mentioning

confidence: 99%

Physical Symptoms Distress Index

Anderson¹,

Hollenberg²,

Williams³

1999

Arch Intern Med

View full text Add to dashboard Cite

Patient-assessed physical symptom distress is a sensitive, simple technique to evaluate the effect of antihypertensive medications on QOL and tolerability, as shown by its ability to detect the improvement associated with COER-verapamil. Depending on the agents involved, the Physical Symptom Distress Index may more closely predict dropout rates than the traditional psychosocial instruments, as suggested by the lower dropout rate in the COER-verapamil group. Thus, in studying treatment effects on QOL, both the distress of physical symptoms and the impact of psychosocial factors should be evaluated.

show abstract

Combination Drug Therapy with Calcium‐Channel Blockers in the Treatment of Systemic Hypertension

Frishman

Landau

Cretkovic

1993

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Calcium-channel blockers have been shown to be both safe and effective for treatment of patients with systemic hypertension. These drugs reduce peripheral vascular resistance predominantly by the inhibition of transmembrane calcium ion fluxes in vascular smooth muscle, and by this mechanism can reduce elevated blood pressure. To maximize blood pressure lowering efficacy in patients, calcium-channel blockers have also been used in combination with other antihypertensive treatments that have included diuretics, beta-adrenergic blockers, and angiotensin-converting enzyme inhibitors.

show abstract

Multicenter comparison of the nifedipine gastrointestinal therapeutic system and long-acting propranolol in patients with mild to moderate systemic hypertension receiving diuretics

Cited by 17 publications

References 17 publications

Long-acting nifedipine in the management of the hypertensive patient

Long-acting nifedipine in the management of the hypertensive patient

Physical Symptoms Distress Index

Combination Drug Therapy with Calcium‐Channel Blockers in the Treatment of Systemic Hypertension

Contact Info

Product

Resources

About